Tildrakizumab is another molecule with action against IL-23, a humanized monoclonal antibody of the IgG1 lambda (IgG1λ) type used in the therapy of moderate to severe psoriasis vulgaris in adults and which in studies has shown efficacy in patients with psoriatic arthropathy. The gene discussed is IL37; the disease is psoriasis vulgaris.